Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Síndrome de Stevens-Johnson/induzido quimicamente , Talidomida/análogos & derivados , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Dexametasona/administração & dosagem , Toxidermias/diagnóstico , Toxidermias/etiologia , Toxidermias/patologia , Humanos , Lenalidomida , Leucemia Plasmocitária/tratamento farmacológico , Leucemia Plasmocitária/patologia , Masculino , Pessoa de Meia-Idade , Síndrome de Stevens-Johnson/diagnóstico , Síndrome de Stevens-Johnson/patologia , Talidomida/administração & dosagem , Talidomida/efeitos adversosRESUMO
Chronic graft versus host disease (cGVHD) is a frequent complication of allogeneic stem cell transplantation. Extensive musculoskeletal and skin involvement may induce severe functional impairment, disability and quality of life deterioration. Physical rehabilitation is recommended as ancillary therapy in these forms, but experiences are sparse. A 39-year-old man affected by musculoskeletal and skin chronic graft versus host disease (cGVHD) was treated with a homecare-based motor rehabilitation program during palliation for disease progression. Significant functional improvement was obtained. Motor rehabilitation should be strongly considered for patients with musculoskeletal cGVHD, both in the palliative and in the curative phase of disease.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias Encefálicas/diagnóstico , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Neoplasias Cutâneas/diagnóstico , Idoso , Benzamidas , Neoplasias Encefálicas/tratamento farmacológico , Aberrações Cromossômicas , Análise Citogenética , Resistencia a Medicamentos Antineoplásicos/genética , Proteínas de Fusão bcr-abl/análise , Doenças Hematológicas , Humanos , Mesilato de Imatinib , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Neoplasias Cutâneas/tratamento farmacológicoRESUMO
The aseptic loosening of the femoral stem may require different treatments due to the complex problems related to the bone resorption (qualitatively and quantitatively): a minimum bone stock loss may result in a periprosthetic resorption that is so severe to make the fixation of the revision prosthesis extremely difficult. The revision surgery of a loosened hip prosthesis is often characterized by a complex reconstruction due to such severe loss of femoral bone tissue. We illustrate our experience with MP-Link modular stem (Waldemar Link, Hamburg, Germany) in cases of severe bone loss of the metaphyseal area and of the proximal third of the femoral shaft, assessing the technological developments (materials and design) over the years and examining the pros and cons of cementless distalfixation modular stems versus the traditional Wagner's stem.
RESUMO
We report a patient with thalassemia intermedia who developed a mediastinal syndrome due to the growth of paravertebral hematopoietic masses in the posterior mediastinum. Because the patient did not receive blood transfusions due to alloimmunization, she was first treated with human recombinant erythropoietin (escalating low-moderate doses) to recover hemoglobin levels, then in association with radiotherapy to prevent a worsening of her anemia. The mean Hb level dramatically increased and peaked at week 11, to 83 g/l, and remained unchanged before and after radiotherapy (81 versus 78 g/l). Immediately after radiotherapy extramedullary hematopoiesis volume decreased by 16.4%.
Assuntos
Eritropoetina/uso terapêutico , Hematopoese Extramedular/efeitos da radiação , Isoanticorpos/análise , Talassemia/fisiopatologia , Talassemia/terapia , Adulto , Feminino , Humanos , Radioterapia , Proteínas Recombinantes , Talassemia/radioterapiaRESUMO
A method for determination of equilibrium constants in heme model systems is proposed, based on successive linear regression applied to spectrophotometric titrations. The method is illustrated for bis(dimethylglyoximate) iron(II) complexes with pyridine and 4-cyanopyridine ligands.